2023 연구자 정보 (2 / 1128)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Lian, Qinshu (Lian, QS) |
Genentech South San Francisco, San Francisco, CA USA |
|
|
[JCR상위 0.2%] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | pierce.chow@duke-nus.edu.sg | ||
|
Ma, Ning (Ma, N) |
Genentech South San Francisco, San Francisco, CA USA |
|
|
[JCR상위 0.2%] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | pierce.chow@duke-nus.edu.sg | ||
|
Nakamura, Shinichiro (Nakamura, S) |
Himeji Red Cross Hosp, Himeji, Hyogo, Japan |
|
|
[JCR상위 0.2%] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | pierce.chow@duke-nus.edu.sg | ||
|
Numata, Kazushi (Numata, K) |
Yokohama City Univ, Med Ctr, Yokohama, Japan |
|
|
[JCR상위 0.2%] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | pierce.chow@duke-nus.edu.sg | ||
|
Park, Kwangsoo (Park, K) |
교신저자 |
North Dakota State Univ, Dept Apparel Merchandising Interior Design & Hospi, 178 E Morrow Lebedeff Hall,NDSU Dept 2610,POB 6050, Fargo, ND 58108 USA Purdue Univ Northwest, White Lodging Sch Hospitality & Tourism Management, Hammond, IN USA |
AAF-6233-2021 Park, Kwangsoo |
0000-0003-4285-8315 Park, Kwangsoo |
[JCR상위 0.2%] Observing disability inclusion in service provision [JCR상위 5.4%] Exploring the role of flow experience and telepresence in virtual reality (VR) concerts |
SSCI | 0.2 |
HOSPITALITY, LEISURE, SPORT & TOURISM SOCIOLOGY |
sgsong@knu.ac.kr kwangsoo.park@ndsu.edu sekim@knu.ac.kr |
|
|
Qin, Shukui (Qin, SK) |
제1저자 | Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China |
|
|
[JCR상위 0.2%] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | pierce.chow@duke-nus.edu.sg | |
|
Son, Joo-Hyuk (Son, JH) |
CHA Univ, CHA Bundang Med Ctr, Comprehens Gynecol Canc Ctr, Seongnam Si, Gyeonggi Do, South Korea |
|
|
[JCR상위 0.2%] Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy | SCIE | 0.2 | SURGERY | drchang@ajou.ac.kr | ||
|
Song, Jae-Yun (Song, JY) |
Korea Univ, Coll Med, Dept Obstet & Gynecol, Med Ctr, Seoul, South Korea |
|
|
[JCR상위 0.2%] Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy | SCIE | 0.2 | SURGERY | drchang@ajou.ac.kr | ||
|
Song, Seobgyu (Song, SBY) |
제1저자 | Kyungpook Natl Univ, Dept Tourism, Daegu, South Korea |
|
|
[JCR상위 0.2%] Observing disability inclusion in service provision | SSCI | 0.2 |
HOSPITALITY, LEISURE, SPORT & TOURISM SOCIOLOGY |
sgsong@knu.ac.kr kwangsoo.park@ndsu.edu |
|
|
Spahn, Jessica H. (Spahn, JH) |
Genentech South San Francisco, San Francisco, CA USA |
|
|
[JCR상위 0.2%] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | pierce.chow@duke-nus.edu.sg | ||
|
Suh, Dong Hoon (Suh, DH) |
Seoul Natl Univ, Dept Obstet & Gynecol, Bundang Hosp, Seongnam, South Korea |
|
|
[JCR상위 0.2%] Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy | SCIE | 0.2 | SURGERY | drchang@ajou.ac.kr | ||
|
Uguen, Thomas (Uguen, T) |
Hop Pontchaillou, Rennes, France |
|
|
[JCR상위 0.2%] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | pierce.chow@duke-nus.edu.sg | ||
|
Wang, Lu (Wang, L) |
Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China |
|
|
[JCR상위 0.2%] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | pierce.chow@duke-nus.edu.sg | ||
|
Wang, Yulei (Wang, YL) |
Genentech South San Francisco, San Francisco, CA USA |
AAG-2845-2020 Wang, Yulei |
0009-0002-9642-9460 Fanello, Silvia |
[JCR상위 0.2%] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | pierce.chow@duke-nus.edu.sg | ||
|
Wen, Xiaoyu (Wen, XY) |
1st Hosp Jilin Univ, Jilin, Peoples R China |
|
|
[JCR상위 0.2%] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | pierce.chow@duke-nus.edu.sg |
페이지 이동: